Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.87
+$0.01 · +0.54%
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Latest quote
$1.87
+$0.01 · +0.54%
After-hours
$1.87
$0.00 · 0.00%
Oct 9, 5:54 PM ET
Regular session · ET · Market data may be delayed.
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Day range
Current $1.87
52-week range
Current $1.87
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
35
Expensive
Sentiment
69
Bullish
Risk
44
Elevated Risk
Momentum
76
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Day range
Current $1.87
52-week range
Current $1.87
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 32.67M USD | 12.71M USD | 3.23M USD | 5.38M USD | 25.15M USD |
| Selling, general, and administrative | 23.71M USD | 6.79M USD | 5.01M USD | 5.68M USD | 7.58M USD |
| Operating expenses | 56.39M USD | 19.49M USD | 8.23M USD | 11.05M USD | 32.73M USD |
| Interest income | 3.82M USD | 1.91M USD | — | — | — |
| Interest expense | — | 23K USD | 23.97K USD | 4.44K USD | 949 USD |
| Depreciation and amortization | — | — | 8K USD | 113.33K USD | 108.98K USD |
| Operating income | −56.39M USD | −19.49M USD | −8.23M USD | −11.05M USD | −32.73M USD |
| Net income | −52.6M USD | −17.6M USD | −7.71M USD | −11.05M USD | −32.47M USD |
Company facts updated Oct 9, 2026.
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM1.75M0.00%77.7B USD0.19%$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI1.57M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 Value ETFIWN618.33K—13.75B USD0.24%$210.87-0.04%
Vanguard Extended Market ETFVXF514.67K0.00%95.4B USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO265.34K0.00%18B USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC212.51K0.02%1.32B USD0.60%$183+0.11%
Fidelity Enhanced Small Cap ETFFESM114.96K—6.41B USD0.28%$45.46+0.46%
ALPS Medical Breakthroughs ETFSBIO87.74K0.05%187.46M USD0.50%$55.04+2.03%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Value ETFIWNVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCFidelity Enhanced Small Cap ETFFESMALPS Medical Breakthroughs ETFSBIOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
